


Disclosures/Conflict of Interest


• I am site-principal investigator for Alzheimer's disease clinical trials funded or sponsored by Eli Lilly, Eisai, Alector, and the National Institute on Aging.

Outline


- 1. Alzheimer's disease background
- 2. Biomarkers
- 3. Prevention strategies
- 4. Current research









Decline	Maintain or improve
Attention	Language
Word-finding	Visuospatial function
Short-term memory	Executive function
	Long-term memory
• Key is that activi (people can com	ties of daily living remain unimpaire pensate)
Tip of the tonguic common	e phenomena, misplacing keys are









Alzheimer's Disease

 Pathology: cerebral atrophy, amyloid plaques, and neurofibrillary tangles












FIGURE 1 Neuropathology of Alzheimer's disease: A. β-smyloid (Aβ) deposits in the form of senile plaques (SP) in a section of the cerebral cortex. Deposits appear as brown patches and are videly distributed, especially in the cerebral cortex (β-smyloid immunohistochemistry). B. neurofibrillarytangles (NFT) in the cerebral cortex appearing as indusion bodies within neurons (tau immunohistochemistry).


Amyloid Cascade Hypothesis















Major targets for Alzheimer's prevention


- 1. Anti-amyloid:
 - Reduce production
 - Reduce toxicity
 - Increase clearance
- 2. Anti-tau
- 3. Metabolism/Inflammation
- 4. Neuroprotection
- 5. Genes
- 6. Multi-domain lifestyle












AHEAD Study: Anti-Amyloid Treatment in Preclinical Alzheimer's Disease with Elevated or Intermediate Amyloid



🕈 Share 🏏 Tweet in Share 🖂 Email 🖨 Print

Amyloid accumulates in the brain a decade or more before memory loss symptoms

This study aims to enroll 1400 healthy older adults with normal memory and intermediate or elevated amyloid, and treat them with an anti-amyloid antibody - lecanemab


Initial screening based on blood test for amyloid


Participants will receive an amyloid PET brain


Intravenous infusions every 2-4 weeks for 4 years

Funding by National Institute on Aging

www.aheadstudy.org










2. Anti-tau

- Antibodies and vaccines under development
- Approaches reduce hyperphosphorylation, reduce aggregation, reduce propagation, increase clearance










5. Targeting Genes

- An inherited (purely genetic) form of AD exists
 - ~1% of all cases
 - Caused by mutations to one of 3 genes APP, PS1, PS2
 - Autosomal dominant
 - Very early-onset 30s, 40s, 50s
- For the other 99% of AD cases
 - Risk is increased approximately 3 fold for having a parent with AD
 - Stronger effect for maternal than paternal family history
 - Later onset 60s +
 - Multiple genes are involved -








5. Gene therapy – focus on APOE carriers


- Generation studies tested a BACE inhibitor in APOE carriers


 halted early due to adverse drug effects
- APOE gene therapy
- Viral vectors
- CRISPR Nobel Prize in 2020


Emmanuelle Charpentier and Jennifer Doudna


















































	kerci							
		Diagnosis	Design	Number	Outcome	Intervention/Measure	Results	
		Diagnosis	Design		SICAL ACTIVITY	inci (cintois (Actual)	A CONTRACT	
	Baum et al. [24]	Mild Dementia (mean MMSE 21/30)	RCT	20	Cognition	Strength training or recreational therapy 6 months	Improved MMSE with physical activity	
	Van de Winkel et al. [25]	Severe Dementia (mean MMSE 13/30)	RCT	15	Cognition	Physical activity + music or conversation 3 months	Improved MMSE with physical activity	
	Weuve et al. [33]		Prospective cohort Nerses' Health Study	766	Cognition	Physical activity and walking	Better cognitive function/less cognitive decline with physical activity and walking	
	Stevens and Killeen [26]	Mild and Severe Dementia (MMSE 9-23/30)	RCT	75	Clock drawing test	Physical activity or social visit or none	Slower cognitive decline with physical activity	
	Lautenschlager et al. [27]	Subjective memory impairment	RCT	308	Dementia	Education and usual care versus physical activity for 6 mos	(Modest) Cognitive improvement at 18 mos	
	0.540.541.0426.4456.05	Healthy subjects	RCT	134	Cognition	Balance versus general training	Cognitive improvement at 6 months	
	Verghese et al. [29]	Healthy subjects	Prospective Cohort Prospective	469	Dementia	Physical activity versus Leisure/Cognitive Activity	Decreased risk for dementia	
	Abbott et al. [30	Healthy subjects	cohort Honolulu Asia Aging	2257	Dementia	Physical activity, walking	Decreased risk for dementia	
	Larson et al. [31]	Healthy subjects	Prospective cohort	1740	Dementia	Physical exercise	Decreased risk for dementia	
Polidori, et al. International J of AD 2010	Cassilhas et al. [32]	Healthy subjects	RCT	62	Cognition	Moderate or High-level resistance training	Improvement of cognition with both lew of resistance trainip	











Is prevention of Alzheimer's disease possible?

- Major risk factors for Alzheimer's disease include aging, genetics, environment, and lifestyle.
- Up to 40% of risk may be reduced –in fact genetic risk may be modifiable in the future
- Recent breakthroughs in biomarker research, allowing detection of Alzheimer's disease in living people before symptoms start, have us poised to test Alzheimer's prevention strategies in the populations at highest risk
- Alzheimer's prevention research is challenging and exciting, and must be inclusive
- Sharing the potential of Alzheimer's prevention in an equitable manner requires commitment on the part of individuals, communities, nations, and the world

Research volunteers hold the key to discovery!

- All research is voluntary
- Many types of studies
 - Healthy adults, people with memory concerns, and people with Alzheimer's disease
 - Observational studies
 - Studies of digital in-home technology
 - Clinical trials of complementary medicine
 - Clinical trials of investigational treatments
- Clinical trials are moving towards prevention
- Clinical trial entry is being honed by imaging and biomarkers
- · Combination therapy may be beneficial



Risk factors for dementia

presents a new life-course n

Contact us Phone: 503-494-7647

THE LANCET

Email: adoutreach@ohsu.edu

Registry: alzactnow.org



